Amniowrap2™ Product Launch Leads Year of Highlights for BioStem Technologies
BioStem provides a business update and highlights recent accomplishments
Preliminary fourth quarter net revenues of $11.5 million and full year 2023 net revenues of $16.7 million
Related news for (BSEM)
- BioStem Technologies Reports Record Second Quarter 2024 Revenue of $74.5 Million
- BioStem Technologies to Report Second Quarter 2024 Financial Results on Monday, August 12, 2024
- BioStem Receives Institutional Review Board (IRB) Approval to Advance a Clinical Study Evaluating AmnioWrap2™ in Diabetic Foot Ulcers
- BioStem Technologies Reports Breakthrough Results with AmnioWrap2® in Retrospective Wound Care Study
- BioStem Technologies to Sponsor MRO Better Half Dash